For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Need to Omit Clinical Trials Pointed Out to Encourage Manufacturing of Mo-99 in Japan
February 28, 2011
- MTPC Voluntarily Withdraws Its Membership from JPMA
February 28, 2011
- Edoxaban Recommended for Approval for VTE
February 28, 2011
- Takeda to Enhance Research Collaboration with Third Parties
February 28, 2011
- Escitalopram to Prop Up Business of Struggling Mochida
February 28, 2011
- Abilify Approved for Maintenance Adjuvant Therapy for Bipolar I Disorder in US
February 28, 2011
- GSK Starts Multinational PIII Study for DMD
February 28, 2011
- Pfizer to Stress Significance of Combining CCB, Statin in One Drug
February 28, 2011
- Increasing Number of Trials Conducted on Concurrent Use of Oral Hypoglycemic Agents
February 28, 2011
- Mylan Aims to Become Top-3 Generic Company in Japan in 5 Years
February 28, 2011
- Takeda to Voluntarily Recall Dasen
February 28, 2011
- Lixisenatide Not Inferior to Exenatide in PIII: sanofi-aventis
February 28, 2011
- ARB + CCB Combination Drugs Ranked in Top Positions in HP, GP Markets: RepTrack Survey
February 28, 2011
- WT1 mRNA Assay Kit Otsuka Approved for MDS
February 28, 2011
- New Drugs Improve Range of Options for Osteoporosis: 2
February 28, 2011
- Otsuka HD to Establish Otsuka Medical Devices
February 28, 2011
- Cooperation beyond National Boundaries Necessary in Asia: JPMA President Hasegawa
February 28, 2011
- Takara Bio to Create Research Reagent Joint Venture in India
February 28, 2011
- Astellas Licenses Tivozanib from AVEO
February 28, 2011
- Healthcare DB Will Promote Development of New Drugs: Mr Mori of PMDA
February 28, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…